Background illustration for clinical trials search

Paid Clinical Trials Glenview

Discover 2,388 paid clinical trials in Glenview, Illinois. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,388

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

for

Non-Muscle Invasive Bladder Neoplasms

Location: Glenview IL, Chicago Ridge IL, Carmel IN, Royal Oak MI,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06919965

Phase 3, Recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

for

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Location: Glenview IL, New Lenox IL, Merrillville IN, Carmel IN,

Sponsor: Dendreon

Sex: Male

Age: 18+

Code: NCT06134232

Phase 2, Recruiting

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for

Myelodysplastic Syndrome

Location: Glenview IL, Evanston IL, Chicago IL, Highland Park IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase 2, Recruiting

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for

Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,

Location: Glenview IL, Lake Forest IL, Maywood IL, Chicago IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06498635

Phase 3, Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

for

Advanced Extrapulmonary Neuroendocrine Carcinoma,

Location: Glenview IL, Lake Forest IL, Chicago IL, Grayslake IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05058651

Phase 2, Phase 3, Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

for

Anatomic Stage II Breast Cancer AJCC v8,

Location: Glenview IL, Chicago IL, Lake Forest IL, Oak Brook IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07391774

Phase 3, Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Glenview IL, Evanston IL, Highland Park IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06672146

Phase 2, Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

for

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: Glenview IL, Lake Forest IL, Chicago IL, Oak Brook IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07195734

Phase 2, Recruiting

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

for

Non-small Cell Lung Cancer

Location: Glenview IL, Lake Forest IL, Chicago IL, Oak Brook IL,

Sponsor: Canadian Cancer Trials Group

Sex: All

Age: 18+

Code: NCT06686771

Phase 3, Recruiting

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

for

Locally Advanced Adrenal Cortical Carcinoma,

Location: Glenview IL, Lake Forest IL, Chicago IL, Oak Brook IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 12+

Code: NCT06900595

Phase 2, Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for

Anatomic Stage I Breast Cancer AJCC v8,

Location: Glenview IL, Lake Forest IL, Chicago IL, Oak Brook IL,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase 3, Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

for

Extensive Stage Lung Small Cell Carcinoma,

Location: Glenview IL, Lake Forest IL, Maywood IL, Chicago IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06769126

Phase 2, Recruiting

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for

Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma,

Location: Glenview IL, Park Ridge IL, Chicago IL, Lake Forest IL,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06958328

Phase 3, Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Glenview IL, Evanston IL, Highland Park IL, Chicago IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase 2, Recruiting

E-Mindfulness Approaches for Living After Breast Cancer

for

Breast Cancer, Depression

Location: Glenview IL, Park Ridge IL, Evanston IL, Chicago IL,

Sponsor: NRG Oncology

Sex: All

Age: 18 - 50

Code: NCT06748222

Phase 3, Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements,

Location: Glenview IL, Lake Forest IL, Chicago IL, Oak Brook IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06649812

Phase 2, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for

Advanced Malignant Solid Neoplasm,

Location: Glenview IL, Park Ridge IL, Evanston IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase 2, Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Glenview IL, Lake Forest IL, Maywood IL, Chicago IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT06031688

Phase 2, Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Glenview IL, Evanston IL, Highland Park IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase 2, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Glenview IL, Park Ridge IL, Evanston IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase 2, Recruiting

Paid Clinical Trials Glenview

Filter results

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Interested in new trials?

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

E-Mindfulness Approaches for Living After Breast Cancer

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)